STOCK TITAN

Baxter International Inc. - BAX STOCK NEWS

Welcome to our dedicated news page for Baxter International (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter International.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Baxter International's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Baxter International's position in the market.

Rhea-AI Summary
Advent International and Warburg Pincus select Franco Negron as CEO of BioPharma Solutions following its divestiture from Baxter International Inc. The closing of the divestiture is expected to occur in the second half of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
-
Rhea-AI Summary
Baxter International Inc. to present at Wells Fargo Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
conferences
-
Rhea-AI Summary
Baxter International appoints Stephen H. Rusckowski to its board of directors and announces the resignation of Michael Mahoney.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
management
Rhea-AI Summary
Baxter International Inc. (NYSE:BAX) reported a 3% increase in second-quarter revenues on a reported basis and 4% on a constant currency basis. The company also reported second-quarter U.S. GAAP earnings (loss) per share of ($0.28) and adjusted EPS of $0.66. Worldwide sales from continuing operations totaled approximately $3.71 billion, representing a 3% increase on a reported basis and 4% on a constant currency basis. The company is making progress on transformational actions announced at the start of 2023 to enhance strategic clarity, market responsiveness, and innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.09%
Tags
-
Rhea-AI Summary
Baxter International Inc. announces the name of its proposed spinoff, Vantive, for its Renal Care and Acute Therapies businesses. Vantive is expected to launch as an independent, publicly traded company by July 2024 or earlier.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
-
Rhea-AI Summary
Baxter International Inc. (NYSE:BAX) launches PERCLOT Absorbable Hemostatic Powder in the U.S. market, expanding its hemostatic product portfolio. PERCLOT is a passive, absorbable hemostatic powder designed for patients with intact coagulation to address mild bleeding, enhancing surgical care and reducing the need for blood transfusions. The product rapidly absorbs water, forming a gelled adhesive matrix that provides a mechanical barrier against further bleeding. The launch aims to optimize patient care and reduce the total cost of care by addressing a broader range of intraoperative bleeding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
dividends
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
Baxter International Inc.

NYSE:BAX

BAX Rankings

BAX Stock Data

20.15B
505.48M
0.37%
92.39%
1.5%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Deerfield

About BAX

baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.